Park Jun Woo, Roh Jong-Lyel, Lee Sang-Wook, Kim Sung-Bae, Choi Seung-Ho, Nam Soon Yuhl, Kim Sang Yoon
Department of Otolaryngology, Asan Medical Centre, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
J Cancer Res Clin Oncol. 2016 May;142(5):1031-40. doi: 10.1007/s00432-015-2108-x. Epub 2016 Jan 7.
The use of excessive and inappropriate medications is a common problem in elderly populations. The use of polypharmacy (PP) and potentially inappropriate medication (PIM) may affect treatment-related morbidities in elderly cancer patients, which has rarely been studied in patients with head and neck cancer (HNC). Here, we evaluate the effects of PP and PIM on treatment and posttreatment courses in elderly HNC patients.
This study included 229 elderly HNC patients who underwent definitive treatment. Medications were carefully recorded, and the prevalences of PP and PIM are reported. We evaluated the associations between PP, PIM, treatment, and posttreatment course in terms of comorbidities, treatment-related toxicity, prolonged hospitalization, and posttreatment noncancer health events.
The prevalences of PP and PIM in our elderly HNC patients were 29.3 and 24.0 %, respectively, and frequently described PIMs include aspirin (12.2 %), calcium channel blockers (4.8 %), benzodiazepines (4.3 %), and nonsteroidal anti-inflammatory drugs (3.9 %). PP and PIM were not significantly associated with treatment-related toxicity, but were associated with modestly increased prolonged hospitalization [odds ratio [OR] 2.30 (95 % confidence interval 0.89-5.95); P = 0.080] and noncancer health events [OR 1.81 (0.99-3.31); P = 0.052], respectively. Among high-risk medications, benzodiazepine [OR 5.09 (1.21-21.5); P = 0.015] and calcium channel blockers [OR 5.69 (1.07-33.25); P = 0.031) were significantly associated with prolonged hospitalization.
Neither PP nor PIM are significantly associated with treatment-related toxicity in elderly HNC patients, but these are associated with modest increases in prolonged hospitalization and noncancer health events.
过度和不恰当地使用药物是老年人群中的常见问题。联合用药(PP)和潜在不适当用药(PIM)可能会影响老年癌症患者与治疗相关的发病率,而对头颈部癌(HNC)患者的这方面研究很少。在此,我们评估PP和PIM对老年HNC患者治疗及治疗后病程的影响。
本研究纳入了229例接受确定性治疗的老年HNC患者。仔细记录用药情况,并报告PP和PIM的发生率。我们从合并症、治疗相关毒性、住院时间延长以及治疗后非癌症健康事件方面评估了PP、PIM、治疗及治疗后病程之间的关联。
我们的老年HNC患者中PP和PIM的发生率分别为29.3%和24.0%,常见的PIM包括阿司匹林(12.2%)、钙通道阻滞剂(4.8%)、苯二氮䓬类药物(4.3%)和非甾体抗炎药(3.9%)。PP和PIM与治疗相关毒性无显著关联,但分别与住院时间适度延长[比值比(OR)2.30(95%置信区间0.89 - ;P = 0.080]和非癌症健康事件[OR 1.81(0.99 - 3.31);P = 0.052]相关。在高风险药物中,苯二氮䓬类药物[OR 5.09(1.21 - 21.5);P = 0.015]和钙通道阻滞剂[OR 5.69(1.07 - 33.25);P = 0.031]与住院时间延长显著相关。
在老年HNC患者中,PP和PIM均与治疗相关毒性无显著关联,但与住院时间适度延长和非癌症健康事件增加相关。